MDS (Myelodysplastic Syndrome) Treatment in Moradabad — Dr. Faran Naim, Hematology & Bone Marrow Transplant Specialist, Jigyasa Hospital
Myelodysplastic syndrome, often shortened to MDS, is a condition that sits in a category many patients haven't heard of until they're diagnosed with it — a bone marrow disorder that isn't quite leukemia, but shares some important connections to it.
Understanding MDS, its risk categories, and treatment options is essential to navigating the condition well. At Jigyasa Hospital, Dr. Faran Naim, our Hematology & Bone Marrow Transplant specialist, provides comprehensive diagnosis, risk assessment, and treatment for MDS in Moradabad.
What Is Myelodysplastic Syndrome?
Myelodysplastic syndrome is a group of disorders in which the bone marrow's blood-forming stem cells are abnormal (dysplastic) and don't mature properly into healthy blood cells. This results in low counts of one or more types of blood cells — red cells, white cells, or platelets — even though the bone marrow itself may appear normally or even increasingly cellular under the microscope.
In essence, the marrow is producing blood cells, but they're defective and often destroyed before they can function properly, or they simply don't mature correctly.
MDS predominantly affects older adults, though it can occur at any age, and in some cases develops following prior chemotherapy or radiation treatment for another condition (referred to as secondary or treatment-related MDS). A meaningful proportion of MDS cases can progress over time to acute myeloid leukemia (AML), which is one of the key reasons risk stratification and monitoring are central to how MDS is managed.
Symptoms of MDS
Symptoms of MDS largely reflect which blood cell lines are most affected, and mild cases may be picked up incidentally on routine blood tests before symptoms develop:
From Low Red Blood Cells (Anemia)
- • Fatigue and weakness
- • Pale skin
- • Shortness of breath
From Low White Blood Cells
- • Frequent or recurrent infections
- • Fevers that may be difficult to control
From Low Platelets
- • Easy bruising
- • Petechiae (small red or purple spots on the skin)
- • Bleeding gums or nosebleeds
Because MDS often develops gradually, particularly in older adults, symptoms are sometimes attributed to aging or other health conditions initially, which is why persistent or worsening blood count abnormalities on routine testing warrant proper hematology evaluation.
How MDS Is Diagnosed
Dr. Naim uses a structured diagnostic approach to confirm MDS, characterize its subtype, and assess risk:
Complete Blood Count (CBC)
Often the first clue, showing low counts of one or more blood cell types. Processed through the hospital's NABL-accredited laboratory.
Peripheral Blood Smear
Examination of blood cells under the microscope, which can reveal characteristic abnormal (dysplastic) features in the blood cells.
Bone Marrow Aspiration and Biopsy
The essential diagnostic test, examining the bone marrow for dysplastic changes in the developing blood cells and determining the percentage of immature cells (blasts) present, which is central to both diagnosis and risk classification.
Cytogenetic Testing
Performed on bone marrow samples to identify specific chromosomal abnormalities, which carry important prognostic information and directly factor into risk scoring.
Molecular/Genetic Mutation Testing
Increasingly used to identify specific gene mutations associated with MDS, which can further refine risk assessment and, in some cases, inform specific treatment choices.
Ruling Out Other Causes of Low Blood Counts
Since several other conditions, including nutritional deficiencies and certain infections, can also cause low blood counts, appropriate testing is done to rule these out before confirming an MDS diagnosis.
Risk Stratification Using IPSS-R
The Revised International Prognostic Scoring System (IPSS-R) is a widely used scoring system that combines the percentage of bone marrow blasts, the severity of specific blood cell count reductions, and cytogenetic findings to classify MDS into risk categories ranging from very low to very high risk. This risk category is one of the most important factors guiding treatment decisions, including the pace and intensity of intervention and the timing of any transplant discussion.
Treatment Options for MDS
Treatment approach is closely tied to the patient's risk category, overall health, and individual goals of care:
Watchful Monitoring
For patients with very low or low-risk MDS without significant symptoms, careful monitoring with regular blood tests may be appropriate initially, reserving more active treatment for when it's needed.
Supportive Care
Including blood transfusions to manage symptomatic anemia, and, where relevant, iron chelation therapy to manage iron buildup in patients receiving frequent transfusions over time.
Growth Factor Therapy
Medications that stimulate the bone marrow to produce more red blood cells or white blood cells can help reduce transfusion needs and infection risk in select patients, particularly with lower-risk MDS.
Hypomethylating Agents
A class of medications commonly used in higher-risk MDS, which can help reduce blast percentage, improve blood counts, and delay progression to leukemia in some patients, generally given in ongoing treatment cycles.
Immunosuppressive Therapy
In select cases, particularly certain lower-risk MDS presentations with specific features, immune-modulating treatment may improve blood counts.
Allogeneic Stem Cell Transplant
The only currently established potentially curative treatment for MDS, generally considered for eligible, fit patients with higher-risk disease, or for lower-risk disease that isn't responding adequately to other treatments. Dr. Naim evaluates transplant candidacy, initiates HLA typing and donor search, and coordinates the transplant pathway and long-term follow-up.
Management of Progression to AML
If MDS progresses to acute myeloid leukemia, treatment shifts to AML-directed chemotherapy protocols, with transplant considered as part of that treatment plan where appropriate.
How Treatment Decisions Are Individualized
Because MDS risk categories and patient circumstances vary so widely, Dr. Naim's approach weighs several factors in developing a treatment plan:
Risk Category
Lower-risk patients are often managed more conservatively, focusing on symptom control and monitoring, while higher-risk patients typically need more active intervention given the greater likelihood of progression.
Age and Overall Fitness
Since allogeneic transplant, the only potentially curative option, carries meaningful risks of its own, patient fitness plays a significant role in determining whether transplant is a reasonable option or whether other treatments better balance benefit and risk.
Transfusion Burden and Symptom Impact
Patients experiencing significant symptoms or frequent transfusion needs may benefit from more active treatment even within a lower-risk category, if quality of life is meaningfully affected.
Patient Preferences and Goals of Care
Especially for older patients or those with other significant health conditions, treatment decisions also take into account personal preferences regarding treatment intensity and quality of life.
Living With MDS
For many patients, particularly those with lower-risk disease, MDS is managed as a chronic condition over an extended period, with periodic monitoring and supportive treatment as needed. Maintaining regular follow-up is important not just for managing current symptoms, but for catching any signs of disease progression early, since risk category and treatment needs can change over time. Nutrition, infection precautions during periods of low white blood cell counts, and open communication with the care team about any new or worsening symptoms all contribute to better day-to-day management.
Structured Risk-Based Approach
Dr. Naim applies established risk stratification tools to guide treatment decisions, ensuring the intensity of treatment matches the individual patient's actual risk profile rather than a generic approach.
Comprehensive Diagnostics
From blood counts and bone marrow examination to cytogenetic and molecular testing, Jigyasa Hospital's NABL-accredited laboratory supports the detailed workup MDS diagnosis and risk assessment require.
Coordinated Long-Term Management
From initial diagnosis through ongoing monitoring, supportive care, and, when appropriate, transplant evaluation and coordination, Dr. Naim manages the full continuum of MDS care.
24/7 Emergency Care
MDS patients, particularly those with significant low blood counts, can experience urgent complications such as severe infection or bleeding. Jigyasa Hospital's round-the-clock emergency services ensure timely care when needed.
Trusted MDS Care in Moradabad
Patients from Moradabad, Rampur, Sambhal, Amroha, Bijnor, and nearby districts choose Jigyasa Hospital for specialist MDS care, NABL lab, PM-JAY empanelment, and comprehensive support.
Why Choose Jigyasa Hospital for MDS Care
MDS requires careful, long-term management with a specialist who understands the nuances of risk stratification and treatment timing. Jigyasa Hospital, located on Rampur Road near Miglani Cinema, Moradabad, offers comprehensive MDS care under Dr. Faran Naim.
- • Structured Risk-Based Approach: Dr. Naim applies established risk stratification tools to guide treatment decisions, ensuring the intensity of treatment matches the individual patient's actual risk profile rather than a generic approach.
- • Comprehensive Diagnostics: From blood counts and bone marrow examination to cytogenetic and molecular testing, Jigyasa Hospital's NABL-accredited laboratory supports the detailed workup MDS diagnosis and risk assessment require.
- • Coordinated Long-Term Management: From initial diagnosis through ongoing monitoring, supportive care, and, when appropriate, transplant evaluation and coordination, Dr. Naim manages the full continuum of MDS care.
- • Ayushman Bharat PM-JAY Empanelment: Given that MDS often requires ongoing, long-term management, PM-JAY empanelment at Jigyasa Hospital helps make this care more accessible to eligible patients.
- • 24/7 Emergency Care: MDS patients, particularly those with significant low blood counts, can experience urgent complications such as severe infection or bleeding. Jigyasa Hospital's round-the-clock emergency services ensure timely care when needed.
Book an Appointment with Dr. Faran Naim
Jigyasa Hospital offers complete specialist-led MDS care under the guidance of Dr. Faran Naim. From accurate diagnosis and risk assessment to supportive care and transplant coordination, comprehensive care is available close to home.
Near Miglani Cinema, Rampur Road, Moradabad 244001
Call Now
7900903333Frequently Asked Questions
Is MDS a type of cancer?
MDS is considered a blood cancer or a pre-cancerous bone marrow disorder, depending on classification systems, and is closely related to leukemia. It's managed by hematologist-oncologists given its potential to progress to acute myeloid leukemia.
Will MDS always turn into leukemia?
Not necessarily. The risk of progression to acute myeloid leukemia varies significantly depending on the specific MDS risk category, with lower-risk MDS having a much lower progression risk than higher-risk disease.
What is the IPSS-R score, and why does it matter?
The Revised International Prognostic Scoring System (IPSS-R) is a tool that combines bone marrow blast percentage, blood count severity, and cytogenetic findings to classify MDS into risk categories, which directly guides treatment intensity and timing decisions, including when to consider transplant.
Is a bone marrow transplant the only cure for MDS?
Allogeneic stem cell transplant is currently the only established potentially curative treatment for MDS, though it's not appropriate or necessary for every patient, particularly those with lower-risk disease who may be managed effectively with other approaches for extended periods.
What are hypomethylating agents?
These are a class of medications commonly used in higher-risk MDS that can help reduce abnormal blast cells and improve blood counts, given in ongoing treatment cycles, sometimes over an extended period.
Can MDS be managed without a transplant?
Yes, many patients, particularly those with lower-risk disease, are managed with supportive care, growth factors, or other medications without proceeding to transplant, sometimes for years.
Why do MDS patients need frequent blood tests?
Regular blood count monitoring helps track disease stability, detect any signs of progression, and guide decisions about when treatment intensity may need to change.
What symptoms of MDS should prompt urgent medical attention?
Signs such as significant unexplained bruising or bleeding, high fever, or symptoms of severe anemia such as chest pain or significant breathlessness should prompt urgent evaluation, given the risk of serious complications from very low blood counts.
Why Patients Choose Us
- 24/7 Emergency & Trauma Care
- Top Specialist Doctors
- Modern ICU & Operation Theatres
- Transparent & Affordable Pricing
- Ayushman Bharat Empanelled
- Cashless Insurance Support
- Multispeciality Under One Roof
Our Location
Near Miglani Cinema,
Rampur Road,
Moradabad 244001